A Randomized, Double-blind Clinical Trial to Evaluate the Lot Consistency, Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine in Adults Aged 40-65 Years
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Pneumococcal 23 valent vaccine Sinovac Biotech (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Sinovac Biotech
- 15 Sep 2023 Status changed from not yet recruiting to completed.
- 17 Feb 2023 New trial record